SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
CSL Limited (CMXHF) trades at a trailing P/E of 15.6, forward P/E of 14.0. Trailing earnings yield is 6.40%, forward earnings yield 7.13%. PEG 1.18.
Criteria proven by this page:
- VALUE (85/100, Pass) — P/E is below market average (15.6); earnings yield beats bond yields (6.40%).
- Forward P/E 14.0 (down from trailing 15.6) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 1.18 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield 6.40% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 7.13% as earnings recover.
Overall SharesGrow Score: 77/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
85/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CMXHF
Valuation Multiples
P/E (TTM)15.6
Forward P/E14.0
PEG Ratio1.18
Forward PEG1.22
P/B Ratio0.00
P/S Ratio3.04
EV/EBITDA0.0
Per Share Data
EPS (TTM)$6.17
Forward EPS (Est.)$6.88
Book Value / Share$0.00
Revenue / Share$31.71
FCF / Share$0.00
Yields & Fair Value
Earnings Yield6.40%
Forward Earnings Yield7.13%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$2.00 |
$4.41B |
$926.93M |
21% |
| 2017 |
$2.24 |
$5.06B |
$1.02B |
20.2% |
| 2018 |
$2.80 |
$5.59B |
$1.27B |
22.8% |
| 2019 |
$4.23 |
$8.54B |
$1.92B |
22.5% |
| 2020 |
$3.20 |
$9.1B |
$1.46B |
16% |
| 2021 |
$3.93 |
$10.27B |
$1.78B |
17.4% |
| 2022 |
$4.80 |
$10.49B |
$2.25B |
21.5% |
| 2023 |
$4.53 |
$13.17B |
$2.19B |
16.7% |
| 2024 |
$5.45 |
$14.8B |
$2.64B |
17.9% |
| 2025 |
$6.17 |
$15.43B |
$3B |
19.5% |
